TABLE 3.
Receptor | Type | Compound | Positive Symptom Models | Negative Symptoms Models | Cognitive Models | References |
---|---|---|---|---|---|---|
mGlu2 | PAM | LY487379 | Reduced NMDAR-HL and AHL;a attenuated AMPH but not PCP-disrupted PPIa | Reduced PCP-induced deficits in social interactionb | Promoted cognitive flexibility in ASSTc | (See footnotes.) |
BINA | Reduced NMDAR-HL;d,f no effect on AHL;d reduced PCP-disrupted PPI;d reduced DOB-induced head twitchese | Reduced MK-801-induced increased immobility in the FSTf | (See footnotes.) | |||
TASP0443294 | Reduced MHLg and NMDAR-HLh | Rescued MK-801-induced social memory deficitsg | (See footnotes.) | |||
JNJ-40411813/ADX71149 | Reduced NMDAR-HL; no effect on AHL; inhibited DOM-induced head twitches | Lavreysen et al., 2015 | ||||
SAR 218645 | No effect on NMDAR-HL or AHL; no effect on hyperactivity in DAT−/− and NR1neo −/− mice; reduced DOI-induced head twitches | Reversed MK-801-induced deficits in NOR; attenuated working memory deficits in Y-maze test in NR1neo−/− mice | Griebel et al., 2016 | |||
mGlu3 | NAM | VU0477950 | Dose-dependent impairment in extinction learning | Walker et al., 2015 | ||
VU0650786 | Blocked the ability of mGlu2/3 agonists to restore trace fear conditioning after PCP administration | Dogra et al., 2021 |
AHL, amphetamine-induced hyperlocomotion; AMPH, amphetamine; ASST, attentional set-shift task; DAT, dopamine transporter; DOB, dimethoxy-bromoamphetamine; HL, hyperlocomotion; METH, methamphetamine; MHL, METH-induced hyperlocomotion; NOR, novel object recognition; NR1neo, NR1 subunit reduced expression.
aGalici et al., 2005.
bHarich et al., 2007.
cNikiforuk et al., 2010.
dGalici et al., 2006.
eBenneyworth et al., 2007.
fKawaura et al., 2016.
gHikichi et al., 2015.
hLavreysen et al., 2015.